诺泰生物：子公司助力siRNA新药LC-1016注射液临床获批

Core Viewpoint - Chengdu Xinzhenhe Pharmaceutical Technology Co., Ltd. has received a clinical acceptance notice from the National Medical Products Administration of China for its siRNA drug LC-1016 injection, indicating a significant advancement in its drug development process [1] Company Summary - Chengdu Xinzhenhe Pharmaceutical Technology Co., Ltd. is focused on the development of siRNA drugs, marking a strategic move into advanced therapeutic areas [1] - The company collaborates with Hangzhou Nuotai Nuohe Biomedical Technology Co., Ltd., a subsidiary of Nuotai Bio, which serves as a core CDMO partner, providing essential raw materials and conducting comprehensive quality research on the raw materials [1] - Nuotai Bio was established in 2009 and went public on the Sci-Tech Innovation Board in 2021, focusing on peptide drugs, small molecule drugs, and strategically expanding into oligonucleotide drugs through a dual-driven model of independent research and CRDMO services [1]